2025-05-17 - Analysis Report
Okay, here's a report analyzing Eli Lilly and Co (LLY) based on the provided data.  It's structured to provide a clear overview of the stock's performance and potential.

**Report: Eli Lilly and Co (LLY) Analysis**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** LLY
*   **Company Description:** Eli Lilly and Co. is a pharmaceutical company that develops and markets pharmaceutical products.
*   **LLY Cumulative Return:** 246.66%
*   **VOO Cumulative Return:** 84.12%
*   **Absolute Divergence (LLY - VOO):** 162.5
*   **Divergence Range:** Max: 312.7, Min: -27.7
*   **Relative Divergence:** 55.9

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the observed period. The relative divergence of 55.9 indicates that LLY's outperformance is in the middle range of its historical performance against VOO.

**Alpha, Beta Analysis**

| Year       | CAGR    | MDD    | Alpha  | Beta | Cap(B) |
|------------|---------|--------|--------|------|--------|
| 2015-2017  | 10.0%   | 55.6%  | -19.0% | 0.1  | 67.7   |
| 2016-2018  | 38.0%   | 58.6%  | 20.0%  | -0.1 | 95.0   |
| 2017-2019  | 49.0%   | 58.6%  | 19.0%  | 0.3  | 110.4  |
| 2018-2020  | 51.0%   | 58.6%  | 25.0%  | 0.2  | 144.7  |
| 2019-2021  | 105.0%  | 60.7%  | 50.0%  | 0.3  | 240.3  |
| 2020-2022  | 100.0%  | 65.0%  | 94.0%  | 0.3  | 322.6  |
| 2021-2023  | 138.0%  | 65.0%  | 122.0% | 0.3  | 519.0  |
| 2022-2024  | 156.0%  | 72.1%  | 139.0% | 0.3  | 691.9  |
| 2023-2025  | 97.0%   | 76.9%  | 65.0%  | 0.2  | 679.9  |

**Analysis:**

*   **CAGR:**  Compound Annual Growth Rate is very strong and has generally been increasing.
*   **MDD:** Maximum Drawdown has also been increasing, suggesting increasing volatility and risk.
*   **Alpha:** Consistently positive and increasing, indicating LLY is generating excess returns compared to its benchmark.
*   **Beta:**  Beta values are relatively low, suggesting LLY is less sensitive to overall market movements than the S&P 500.
*   **Market Cap:** The Market capitalization has increased significantly over the years.

**2. Recent Price Action**

*   **Current Price:** $757.39
*   **Last Market Close:** {'price': 757.39, 'previousClose': 731.79, 'change': 3.5}
*   **5-day Moving Average:** 741.574
*   **20-day Moving Average:** 803.28
*   **60-day Moving Average:** 819.6598

**Analysis:** The current price is below both the 20-day and 60-day moving averages, suggesting a short-term downtrend. The significant positive change from the previous close suggests a recent rebound, but the price still needs to break above the moving averages to confirm a bullish reversal.

**3. Market Risk Indicator (MRI) and Return Expectation**

*   **MRI:** 0.3475 (Low Risk)
*   **RSI:** 32.93 (Oversold)
*   **PPO:** -1.01 (Below Zero Line)
*   **Recent (20-day) Relative Divergence Change:** -1.8 (Short-term Decrease)
*   **Expected Return:** 121.5%

**Analysis:**

*   **MRI:** Low Risk indicates the stock is relatively less risky.
*   **RSI:** The RSI suggests the stock is oversold, potentially indicating a buying opportunity.
*   **PPO:** The PPO being below zero confirms the recent downtrend.
*   **Relative Divergence Change:** The negative change indicates recent underperformance relative to the S&P 500.
*   **Expected Return:** A high expected return suggests strong long-term growth potential, exceeding the S&P 500.
*   **Price Change Reflection:** The significant price change from the previous close (3.5) suggests some positive news or event has impacted the stock.

**4. Recent News & Significant Events**

*   **2025-05-16:** Major business developments, regulatory changes, or market events.
*   **2025-05-15:** Analyst discussions on recent performance and outlook.
*   **2025-05-14:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-05-13:** Market experts highlight both risks and opportunities.

**Analysis:** The recent news indicates potential catalysts for volatility and highlights the importance of monitoring company announcements and expert opinions.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-05-01 | 3.07 | 12.73 B$    |
| 2024-10-30 | 1.08 | 11.44 B$    |
| 2024-08-08 | 3.29 | 11.30 B$    |
| 2024-04-30 | 2.49 | 8.77 B$     |
| 2025-05-01 | 2.49 | 8.77 B$     |

**Analysis:**  Earnings per share (EPS) and revenue have shown significant growth over the recent quarters. The most recent EPS is strong, suggesting positive performance. Revenue has also increased substantially, indicating strong demand for LLY's products.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |
| 2024-06-30   | $11.30B    | 80.80%        |
| 2024-03-31   | $8.77B     | 80.91%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE       |
|--------------|-------------|-----------|
| 2025-03-31   | $15.76B     | 17.50%    |
| 2024-12-31   | $14.19B     | 31.07%    |
| 2024-09-30   | $14.24B     | 6.81%     |
| 2024-06-30   | $13.56B     | 21.88%    |
| 2024-03-31   | $12.81B     | 17.51%    |

**Analysis:**

*   **Revenue and Profitability:** Revenue has been consistently increasing, and the profit margin remains exceptionally high.
*   **Capital and Profitability:** Equity has increased over the period, reflecting the company's growth. The Return on Equity (ROE) fluctuates, but generally indicates good profitability.

**7. Overall Summary and Recommendations**

Eli Lilly and Co. (LLY) exhibits a strong financial profile with significant growth in revenue, earnings, and market capitalization.  It has substantially outperformed the S&P 500 historically, with an excellent alpha.

*   **Positive Factors:**
    *   High Expected Return suggests strong future growth potential.
    *   Oversold RSI and recent price rebound may indicate a short-term buying opportunity.
    *   Strong and increasing revenue and EPS.
    *   High profit margins and ROE demonstrate profitability.
*   **Potential Risks:**
    *   Recent short-term price decline.
    *   Increasing MDD reflect greater volatility and risk.
    *   Need to monitor news and company announcements for catalysts.

**Recommendation:** The data suggests a positive long-term outlook for LLY. While recent price action indicates a short-term correction, the strong financials, high expected return, and positive long-term performance warrant consideration for long-term investment, especially given the current oversold condition. However, investors should be aware of the increasing volatility and monitor news and company announcements closely.

